505 related articles for article (PubMed ID: 1941122)
1. Expression and modulation of major histocompatibility antigens on murine primary brain tumor in vitro.
Akbasak A; Oldfield EH; Saris SC
J Neurosurg; 1991 Dec; 75(6):922-9. PubMed ID: 1941122
[TBL] [Abstract][Full Text] [Related]
2. Lytic susceptibility of target cells to cytotoxic T cells is determined by their constitutive major histocompatibility complex class I antigen expression and cytokine-induced activation status.
Ritter M; Huber C; Auböck J; Pohl-Markl H; Troppmair J; Herold M; Gächter A; Nussbaumer W; Böck G; Nachbaur D
Immunology; 1994 Apr; 81(4):569-77. PubMed ID: 7913694
[TBL] [Abstract][Full Text] [Related]
3. Schwann cells co-cultured with stimulated T cells and antigen express major histocompatibility complex (MHC) class II determinants without interferon-gamma pretreatment: synergistic effects of interferon-gamma and tumor necrosis factor on MHC class II induction.
Kingston AE; Bergsteinsdottir K; Jessen KR; Van der Meide PH; Colston MJ; Mirsky R
Eur J Immunol; 1989 Jan; 19(1):177-83. PubMed ID: 2493382
[TBL] [Abstract][Full Text] [Related]
4. Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro.
Weber JS; Rosenberg SA
Cancer Res; 1988 Oct; 48(20):5818-24. PubMed ID: 3139284
[TBL] [Abstract][Full Text] [Related]
5. Differential modulation by tumor necrosis factor and immune interferon of HLA class-II antigens expressed by melanoma cells.
Maio M; Gulwani B; Morgano A; Ferrone S
Int J Cancer; 1989 Sep; 44(3):554-9. PubMed ID: 2506138
[TBL] [Abstract][Full Text] [Related]
6. HLA-class-I and -class-II expression on renal tumor xenografts and the relation to sensitivity for alpha-IFN, gamma-IFN and TNF.
Beniers AJ; Peelen WP; Debruyne FM; Schalken JA
Int J Cancer; 1991 Jul; 48(5):709-16. PubMed ID: 1906431
[TBL] [Abstract][Full Text] [Related]
7. Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme.
Yang I; Kremen TJ; Giovannone AJ; Paik E; Odesa SK; Prins RM; Liau LM
J Neurosurg; 2004 Feb; 100(2):310-9. PubMed ID: 15086239
[TBL] [Abstract][Full Text] [Related]
8. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
9. Cytokine (IFN-alpha, IFN-gamma, IL-1-alpha, TNF-alpha)-induced modulation of HLA cell surface expression in human breast cancer cell lines.
Sedlák J; Speiser P; Zeillinger R; Krugluger W; Wiltschke C; Kubista E; Chorváth B
Neoplasma; 1992; 39(5):269-72. PubMed ID: 1436241
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of interferon induction of class I major histocompatibility complex antigen expression by human tumor necrosis factor in small cell lung cancer cell lines.
Marley GM; Doyle LA; Ordóñez JV; Sisk A; Hussain A; Yen RW
Cancer Res; 1989 Nov; 49(22):6232-6. PubMed ID: 2553249
[TBL] [Abstract][Full Text] [Related]
11. [A novel experimental approach to immunotherapy against malignant brain tumor with the mouse IFN-gamma gene transfer].
Nishihara K
Nihon Geka Hokan; 1989 Jan; 58(1):18-42. PubMed ID: 2508589
[TBL] [Abstract][Full Text] [Related]
12. Effects of IFN-gamma and interleukin-1beta on major histocompatibility complex antigen and intercellular adhesion molecule-1 expression by 9L gliosarcoma: relevance to its cytolysis by alloreactive cytotoxic T lymphocytes.
Schiltz PM; Gomez GG; Read SB; Kulprathipanja NV; Kruse CA
J Interferon Cytokine Res; 2002 Dec; 22(12):1209-16. PubMed ID: 12581494
[TBL] [Abstract][Full Text] [Related]
13. MHC class II antigen expression is not induced on murine epidermal keratinocytes by interferon-gamma alone or in combination with tumour necrosis factor-alpha.
Yeoman H; Anderton JG; Stanley MA
Immunology; 1989 Jan; 66(1):100-5. PubMed ID: 15493270
[TBL] [Abstract][Full Text] [Related]
14. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes.
Ogasawara M; Rosenberg SA
Cancer Res; 1993 Aug; 53(15):3561-8. PubMed ID: 8101762
[TBL] [Abstract][Full Text] [Related]
15. Selective regulation of ICAM-1 and major histocompatibility complex class I and II molecule expression on epidermal Langerhans cells by some of the cytokines released by keratinocytes and T cells.
Chang CH; Furue M; Tamaki K
Eur J Immunol; 1994 Nov; 24(11):2889-95. PubMed ID: 7957579
[TBL] [Abstract][Full Text] [Related]
16. Modulation by canine interferon-gamma of major histocompatibility complex and tumor-associated antigen expression in canine mammary tumor and melanoma cell lines.
Whitley EM; Bird AC; Zucker KE; Wolfe LG
Anticancer Res; 1995; 15(3):923-9. PubMed ID: 7645983
[TBL] [Abstract][Full Text] [Related]
17. Class II transactivator-mediated regulation of major histocompatibility complex class II antigen expression is important for hematopoietic progenitor cell suppression by chemokines and iron-binding proteins.
Broxmeyer HE; Cooper S; Hangoc G; Chang CH
Exp Hematol; 2006 Aug; 34(8):1078-84. PubMed ID: 16863914
[TBL] [Abstract][Full Text] [Related]
18. MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma.
Bander NH; Yao D; Liu H; Chen YT; Steiner M; Zuccaro W; Moy P
Prostate; 1997 Dec; 33(4):233-9. PubMed ID: 9397194
[TBL] [Abstract][Full Text] [Related]
19. Modified immunoregulation associated with interferon-gamma treatment of rat glioma.
Oshiro S; Liu Y; Fukushima T; Asotra K; Black KL
Neurol Res; 2001 Jun; 23(4):359-66. PubMed ID: 11428516
[TBL] [Abstract][Full Text] [Related]
20. Interferon-gamma, interferon-alpha/beta, and tumor necrosis factor differentially affect major histocompatibility complex class I expression in murine leukemia virus-induced tumor cell lines.
Klyczek KK; Murasko DM; Blank KJ
J Immunol; 1987 Oct; 139(8):2641-8. PubMed ID: 3116091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
